Showing results (161-170 of 203) with videos related to
Sort By:
Pageof 21
Blood|August 10, 1999
Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cellsJ C Byrd, C Shinn, R Ravi, et al.Cancer Treatment Reports|September 1, 1977
Peritoneoscopy: a technique to evaluate therapeutic efficacy in non-Hodgkin's lymphoma patientsT Anderson, R A Bender, S H Rosenoff, et al.Journal of the National Cancer Institute|December 21, 1994
Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor modelJ J Casciari, M G Hollingshead, M C Alley, et al.Cancer Research|October 1, 1979
Phase I trial of N-(phosphonacetyl)-L-aspartateC Erlichman, J M Strong, P H Wiernik, et al.Annals of Internal Medicine|October 1, 1976
Sepsis with a new species of CorynebacteriumK R Hande, F G Witebsky, M S Brown, et al.Cancer Chemotherapy and Pharmacology|October 12, 2012
Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancerB F Chu, M J Karpenko, Z Liu, et al.Journal of the National Cancer Institute|August 2, 1989
4-Ipomeanol: a novel investigational new drug for lung cancerM C Christian, R E Wittes, B Leyland-Jones, et al.Blood|March 1, 1981
The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancyM R Grever, M F Siaw, W F Jacob, et al.Seminars in Oncology|July 6, 2000
Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disordersJ C Byrd, M R Grever, J K Waselenko, et al.Journal of the National Cancer Institute|January 4, 1995
Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeletonA M Senderowicz, G Kaur, E Sainz, et al.Pageof 21